An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina

Trial Profile

An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 28 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 14 Jun 2017 Planned primary completion date changed from 1 Nov 2019 to 15 Nov 2022.
    • 14 Jun 2017 Planned initiation date changed from 1 Mar 2017 to 18 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top